A large proportion of breast cancers express receptors for estrogen/progesterone (hormone receptor-positive, HR+) while lacking the over-expression of HER2 (HER2−) (corresponding mainly to the luminal A PAM50 categorization). This evidence concerns the gene ERBB2 and breast carcinoma.